中药联合α-干扰素对慢性乙型肝炎血清HBsAg的影响  

Influence of Chinese Patent Medicines Combined with α-IFN on Serum HBsAg in Chronic Hepatitis Patients

作　　者：成晓燕[1] 杨诗杰[2] 吴进军[3] 项岚[4] 孙丽[3] 王娜[3] 蔡定彬[3] 苏汝好[3] 

机构地区：[1]广东医学院,广东湛江524023 [2]中国疾病控制中心寄生虫病预防控制所,上海200025 [3]广东医学院附属医院,广东湛江524001 [4]开封市医科所,河南开封475000

出　　处：《时珍国医国药》2009年第6期1352-1354,共3页Lishizhen Medicine and Materia Medica Research

基　　金：广东省科技攻关项目(No.A98040)

摘　　要：目的评价中药联合α-干扰素对慢性乙型肝炎患者血清HBsAg的影响。方法按照系统评价的原则制定检索策略,收集符合纳入标准的研究并采集相关信息和Meta分析。结果20篇文献符合纳入标准,10个联合治疗方案、1 921名患者纳入研究,苦参素联合α-干扰素治疗慢性乙型肝炎疗程为3个月,6个月时相对危险度分别为RR1.71,1.83;95%可信区间CI(0.82,3.56),(0.92,3.65),联合组与对照组相比无统计学意义。其他联合方案与对照组相比均无统计学意义。结论就现有的研究来看,还不能得出中药联合α-干扰素治疗慢性乙型肝炎对血清HBsAg转阴率优于单用α-干扰素的结论。Objective To study the influence of Chinese Patent Medicines combined with α - interferon on HBsAg chronic hepatits B patients. Methods Search strategy was formulated according to the Cochrane systematic review, related information of the literatures met inclusion criteria was gathered. Results 20 trials met the inclusion criteria, 10 sorts of Chinese Patent Medicines, 10 sorts of treatment prescription, 1921 patients were included. No significant statistic difference between the two groups was identified after treatment. Conclusion According to existing literatures, we could not reach a conclusion that the therapeutic effect of Chinese Patent Medicines combined with α-interferon on serum-HBsAg in chronic hepatitis B patients were surpass over that of α- interferon alone.

关 键 词：苦参素 中药 Α-干扰素 慢性乙型肝炎 血清HBSAG META分析 

分 类 号：R284.2[医药卫生—中药学]